Navigation Links
Phase 3 data show viral cure rates achieved in a broad range of patients with genotype-1 hepatitis C taking investigational compound faldaprevir plus PegIFN/RBV
Date:11/2/2013

A inhibitor, PPI-668, with and without ribavirin.

Further, data from other Boehringer Ingelheim studies will be presented at AASLD. The aim of these studies is to better understand faldaprevir's drug-drug interaction profile in patients who are taking birth control and common anti-addiction medications. Additionally, a study evaluating faldaprevir in patients who have renal impairment will also be presented. Studies have shown that there is a higher prevalence of chronic kidney disease, also known as renal impairment, in patients with HCV making it important to understand the activity of HCV treatments in this population.  

Faldaprevir and deleobuvir are investigational compounds and not approved by the FDA. Their safety and efficacy have not been established.

Abstracts from The Liver Meeting® can be accessed on the AASLD website at www.aasld.org.

About Boehringer Ingelheim in Hepatitis C Virus (HCV)
In partnership with the scientific community, our clinical trial program is rigorously designed to find answers to the challenges that HCV patients face, including those who are the most difficult to cure. Our pivotal HCV clinical trials for faldaprevir and deleobuvir are comprised of two multi-trial programs, STARTVerso™ and HCVerso®.

Faldaprevir is an investigational, oral protease inhibitor that is specifically designed to target viral replication in the liver. Boehringer Ingelheim is developing faldaprevir as a core component of both interferon-based and interferon-free hepatitis C treatment regimens. STARTVerso is a multi-study Phase 3 trial program that evaluates faldaprevir combined with PegIFN/RBV. The four trials that make up this program study the combination in treatment-naive, treatment-experienced and HIV/HCV coinfected patients with chronic genotype-1 HCV. Deleobuvir is an investigational NS5B non-nucleoside pol
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015 Research and Markets ... the "Latest Regulations on Pharmaceutical International Multi-Center ... offering. This is first time in ... on international multi-center clinical trials of drugs in ... to be implemented on March 1, 2015. The ...
(Date:5/22/2015)... -- In a sweeping analysis assessing the current state of ... researchers conclude that there remains considerable room for improving ... groups, but especially for adolescents and young adults. The ... underscoring the need to address barriers to care and ... 1 patients achieve optimal metabolic control. ...
(Date:5/22/2015)... , May 22, 2015 AcelRx Pharmaceuticals, Inc. ... on the development and commercialization of innovative therapies for ... that interim chief executive officer Howie Rosen ... chief financial officer Tim Morris will be ... the two presentations are as follows: Jefferies ...
Breaking Medicine Technology:2015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2
... RESEARCH TRIANGLE PARK, N.C. , June 15 ... co-promotion arrangement with Novartis Vaccines to jointly market and sell ... , , ... (Rabies Immune Globulin [Human]), an essential component of rabies post-exposure ...
... SPRING, Md. , June 15 The Food and Drug Administration ... sold with droppers that could allow excessive dosing of Vitamin D to infants. ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) , ... The FDA also advised manufacturers of liquid ...
Cached Medicine Technology:Talecris Forms Partnership to Co-Promote Life-Saving Rabies Products 2Talecris Forms Partnership to Co-Promote Life-Saving Rabies Products 3Talecris Forms Partnership to Co-Promote Life-Saving Rabies Products 4Talecris Forms Partnership to Co-Promote Life-Saving Rabies Products 5Talecris Forms Partnership to Co-Promote Life-Saving Rabies Products 6FDA Cautions on Accurate Vitamin D Supplementation for Infants 2
(Date:5/23/2015)... (PRWEB) May 23, 2015 On May ... powers of a youngster's yogic power learned through meditation ... Nithyananda Swami in Bangalore, India. , Yogamaatha, a nine-year-old ... than 50 high profile professionals attending the 2015 Business ... reading fluently -- blindfolded. , In a demonstration ...
(Date:5/23/2015)... May 23, 2015 On May 16, the ... The event was a 5k mud obstacle run that raised ... 2 million people worldwide, and the reason we participated was ... Chad Davis, owner of Farrell’s eXtreme Bodyshaping. “One-hundred percent of ... Society.” , The event was not only attended by eXtreme ...
(Date:5/23/2015)... 23, 2015 Add High-Quality prismatic refractions into ... Studios. , It's as simple as dragging and dropping footage ... tool for full effect. , Including over 80 stunning ... 5k sensors making this the ultimate bundle for adding prismatic ... in this package are movie files designed for Final Cut ...
(Date:5/22/2015)... Francisco, CA (PRWEB) May 22, 2015 ... hosting two exciting events in June. They will hold ... Professional Doctorate and a two-day class on Classical Chinese ... p.m. June 3, Dr. Steve Given, the Dean of ... will discuss the new First Professional Doctorate program. ACTCM ...
(Date:5/22/2015)... 2015 Following yesterday’s announcement that Ascenta ... US-based health brand Nature’s Way, Marc St-Onge has affirmed ... Ascenta Skin is an integral part of the agreement ... opportunity to further develop Ascenta Skin into a leading ... is a breakthrough, anti-aging skincare supplement featuring 6 active ...
Breaking Medicine News(10 mins):Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:ACTCM Announces Upcoming June Events 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2
... needed from the rich countries to achieve the universal goal ... ,Five times more money is needed to meet the ... of papers published online by the Lancet today. It coincides ... the Norwegian government. , ,According to Timothy Powell-Jackson ...
... extensively used to treat acne can cause depression. This ... ,Recently, the drug- Roaccutane, which effectively cures ... side-effects like suicidal behaviour. Though the packaging of the ... of such side-effects is not known.,It has not been ...
... had Shah Rukh Khan at the ceremony in Bangalore. Biocon's ... be priced at 40 percent of what similar drugs marketed ... of MAb developers worldwide. We want to be a key ... drug was undergoing regulatory processes for South Asian markets, but ...
... contend with now - a sharp rise in HIV/AIDS cases. ... insurgency-hit state, unofficial estimates peg the number at 25,000.// ... Grassroots Features. The northern state lies in a low prevalence ... (STD-infected) at 0.95 percent and among the low-risk groups at ...
... Claudia Mitchell, was a United States Marine who lost her arm in ... with a new prosthetic arm that is controlled by her own nerves. ... a steak which was the first that she had been able to ... ago. She said, “That was a very big thing for me.” ...
... site at the University of California, San Diego (UCSD) ... from around the world// to self-report adverse effects of ... ,“This line of research is important because ... cholesterol are familiar with the benefits of statins and ...
Cached Medicine News:Health News:Child death reduction needs five times more funds 2Health News:Acne drug may cause depression 2Health News:Kashmir Grapples with Growing AIDS 2Health News:Kashmir Grapples with Growing AIDS 3Health News:Bionic Women –No longer the Stuff of Science Fictio 2Health News:Patients Can Report Statins' Adverse Effects on New Web Site 2
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
... insulin pen with a memory. HumaPen MEMOIR records the ... (including priming doses). You can see exactly when and ... you simply "dial" your dose by turning the dose ... initial set-up. If you dial too many units, you ...
Medicine Products: